Prevalence and clinicopathologic characteristics of multiple myeloma with cutaneous involvement: A case series from Korea

Woo, Yu Ri; Kim, Jong Sic; Lim, Ji Hong; Hwang, Sung Ho; Kim, Miri; Bae, Jung Min; Park, Young Min; Min, Chang‐Ki; Kim, Dong-Wook

doi:10.1016/j.jaad.2017.08.054

Cited by 23 publications

(38 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42 Seven other papers examined cutaneous involvement by multiple myeloma. 5,15,28,41,48,70,71 Eleven papers examined kappa and lambda restriction in mucosal lesions, including oral, ocular and genital mucosa. 9,10,23,28,33,35,45,50,56,58,60 When histopathologic features were fully described, plasma cells were inconspicuous to absent in FCL, 28,37,41 MCL, 28 DLBCL, 37,41 and most cases of CLL/SLL, 25,26,39,55 and light chain restriction was recognized in some cases by weak staining of Bcells.…”

Section: Resultsmentioning

confidence: 99%

“…72 The clinical impression was not included in many studies. 5,12,14,16,23,[28][29][30][31][32][33][34][35]37,38,41,43,46,47,[49][50][51][52][56][57][58]60,[65][66][67][69][70][71][72][73] 4 | DISCUSSION Flow cytometry (FC) also detects light chain restriction. It is often used to detect surface light chain, but can be used to detect cytoplasmic light chain following a permeabilization procedure.…”

Section: Resultsmentioning

confidence: 99%

“…Unfortunately, many studies do not specify the kappa and lambda ratio that was used to determine light chain restriction. [23][24][25][26][28][29][30][31][32][34][35][36][38][39][40][42][43][44][45][47][48][49][50][51][52][53][54][55][57][58][59][62][63][64][65][66][68][69][70][71]73 Complicating matters, universally accepted standards for kappa to lambda ratios that signify light chain restriction and monotypia have not been established.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Kappa and lambda immunohistochemistry and in situ hybridization in the evaluation of atypical cutaneous lymphoid infiltrates

et al. 2020

View full text Add to dashboard Cite

Background: Atypical cutaneous lymphoid infiltrates are challenging lesions in dermatopathology. We present a summary of the literature regarding kappa and lambda immunohistochemistry (IHC) and in situ hybridization (ISH) in the evaluation of atypical cutaneous or mucosal lymphoid infiltrates. Methods: Relevant articles from 1967 to 2018 in the English language were identified and summarized. In the absence of larger studies, case series of n ≥ 3 were included. Results: Sixty-three articles assessing kappa and lambda IHC and/or ISH were identified. Most focused on marginal zone lymphomas. Other lymphomas included follicle center lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, lymphoplasmacytic lymphoma, plasmablastic lymphoma, multiple myeloma, monoclonal gammopathy of undetermined significance, and polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS). Non-neoplastic lesions included reactive lymphoid hyperplasia, cutaneous plasmacytosis, connective tissue disease, IgG4-related disease, acrodermatitis chronic atrophicans, Zoon balanitis, dermatitides, and infiltrates around epithelial dysplasias/neoplasias. Conclusion: Kappa and lambda IHC and ISH are useful tools in the evaluation of cutaneous B-cell lymphomas and plasma cell neoplasms. The literature supports that the detection of light-chain restriction by IHC and ISH is one of the most useful findings in the differential diagnosis of reactive lymphoid hyperplasia vs B-cell lymphoma with plasmacytic differentiation.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Kappa and lambda immunohistochemistry and in situ hybridization in the evaluation of atypical cutaneous lymphoid infiltrates

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Less than 2% of patients with MGUS have skin manifestations: angioneurotic edema, dermal mucinosis, lupus erythematosus, psoriasis, pustular subcorneal dermatosis, myxedematous lichen, and pyoderma gangrenosum have been reported [18]. Patients with cutaneous involvement showed a lower overall survival compared with those without cutaneous involvement [19].…”

Section: Differential Diagnosismentioning

confidence: 99%

Multiple Myeloma Mimicking a Small Vessel Vasculitis Presentation

Mejía-Zuluaga

Lacouture

Gaviria

et al. 2020

Case Reports in Rheumatology

View full text Add to dashboard Cite

Multiple myeloma can have different clinical manifestations, and not all patients present with classic CRAB component. We describe a 46-year-old woman admitted to our hospital with a complaint of a bluish-to-black discoloration of the second toe that was rapidly progressive and acute kidney injury. We documented a Kappa light chain monoclonal gammopathy, increased presence of plasmacytes in bone marrow aspiration, and multiple lytic bone lesions, which led to a diagnosis of multiple myeloma. Although multiple myeloma presenting with blue finger syndrome is uncommon, it must always be considered as a differential diagnosis with this clinical finding.

show abstract

“…Although multiple myeloma (MM) is an uncommon disease with a lifetime risk of 1 in 132 in the United States [1], recent advances in MM treatment have prolonged survival and led to an increased disease prevalence. Cutaneous involvement in MM most commonly results from metastasis and direct extension of disease from nearby tumor foci, presenting as palpable violaceous nodules on the trunk and extremities [2]. A recent Korean case series of 1,228 patients reported direct cutaneous involvement in only 1.14% of patients with MM.…”

Section: Introductionmentioning

confidence: 99%